Resistin - the link between adipose tissue dysfunction and insulin resistance in patients with obstructive sleep apnea

Journal of Diabetes and Metabolic Disorders

Volumn 12, Issue 1, 2013, Pages

  Cherneva, Radostina Vlaeva ^a   Georgiev, Ognian Borisov ^a   Petrova, Daniela Stoichkova ^a   Mondeshki, Tsanko Lilianov ^a   Ruseva, Sylvia Rumenova ^a   Cakova, Adelina Dimitrova ^a   Mitev, Vanio Ivanov ^a  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

Author keywords

Diabetes; Impaired glucose tolerance; Insulin resistance; Normal glucose metabolism; OSA; Resistin

Indexed keywords

8 ISOPROSTANE; CHOLESTEROL; FATTY ACID; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RESISTIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; FATTY ACID DERIVATIVE; ISOPROSTANE DERIVATIVE;

ADIPOSE TISSUE; ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; DISORDERS OF CARBOHYDRATE METABOLISM; FATTY ACID DESATURATION; FEMALE; GLUCOSE METABOLISM; HORMONE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; OBESITY; OXIDATIVE STRESS; POLYSOMNOGRAPHY; SLEEP DISORDERED BREATHING; APNEA HYPOPNEA INDEX; DESATURATION INDEX; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE MARKER; DYSGLYCEMIA; EARLY DIAGNOSIS; HOMEOSTASIS MODEL ASSESSMENT INDEX; HORMONE DETERMINATION; PATHOPHYSIOLOGY; RESISTIN BLOOD LEVEL; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

EID: 84882784543     PISSN: None     EISSN: 22516581     Source Type: Journal    
DOI: 10.1186/2251-6581-12-5     Document Type: Article

References (43)

1. Hatipoglu U, Rubinstein I. Inflammation and obstructive sleep apnea syndrome pathogenesis: a working hypothesis. Respiration 2003, 70:665-671. 10.1159/000075218, 14732803.
2. Tanriverdi H, Evrengul H, Kara CO, Kuru O, Tanriverdi S, Ozkurt S, Kaftan A, Kilic M. Aortic stiffness, flow-mediated dilatation and carotid intima-media thickness in obstructive sleep apnea: non-invasive indicators of atherosclerosis. Respiration 2006, 73:741-750. 10.1159/000093531, 16717439.
3. Minoguchi K, Yokoe T, Tazaki T, Minoguchi H, Tanaka A, Oda N, Okada S, Ohta S, Naito H, Adachi M. Increased carotid intima-media thickness and serum inflammatory markers in obstructive sleep apnea. Am J Respir Crit Care Med 2005, 172:625-630. 10.1164/rccm.200412-1652OC, 16120716.
4. Ip MS, Lam B, Ng MM, Lam WK, Tsang KW, Lam KS. Obstructive sleep apnea is independently associated with insulin resistance. Am J Respir Crit Care Med 2002, 165:670-676.
5. Punjabi NM, Shahar E, Redline S, Gottlieb DJ, Givelber R, Resnick HE. Sleep-disordered breathing, glucose intolerance, and insulin resistance: the Sleep Heart Health Study. Am J Epidemiol 2004, 160:521-530. 10.1093/aje/kwh261, 15353412.
6. McArdle N, Hillman D, Beilin L, Watts G. Metabolic risk factors for vascular disease in obstructive sleep apnea: a matched controlled study. Am J Respir Crit Care Med 2007, 175:190-195.
7. Coughlin SR, Mawdsley L, Mugarza JA, Calverley PM, Wilding JP. Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome. Eur Heart J 2004, 25:735-741. 10.1016/j.ehj.2004.02.021, 15120883.
8. Lam JC, Lam B, Lam CL, Fong D, Wang JK, Tse HF, Lam KS, Ip MS. Obstructive sleep apnea and the metabolic syndrome in community- based Chinese adults in Hong Kong. Respir Med 2006, 100:980-987. 10.1016/j.rmed.2005.10.003, 16337115.
9. Yannakoulia M, Yiannakouris N, Bluher S, Matalas AL, Klimis-Zacas D, Mantzoros CS. Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans. J Clin Endocrinol Metab 2003, 88:1730-1736. 10.1210/jc.2002-021604, 12679465.
10. Vozarova de Courten B, Degawa-Yamauchi M, Considine RV, Tataranni PA. High serum resistin is associated with an increase in adiposity but not a worsening of insulin resistance in Pima Indians. Diabetes 2004, 53:1279-1284. 10.2337/diabetes.53.5.1279, 15111497.
11. Degawa-Yamauchi M, Bovenkerk JE, Juliar BE, Watson W, Kerr K, Jones R, Zhu Q, Considine RV. Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab 2003, 88:5452-5455. 10.1210/jc.2002-021808, 14602788.
12. McTernan PG, McTernan CL, Chetty R, Jenner K, Fisher FM, Lauer MN, Crocker J, Barnett AH, Kumar S. Increased resistin gene and protein expression in human abdominal adipose tissue. J Clin Endocrinol Metab 2002, 87:2407-2411. 10.1210/jc.87.5.2407, 11994397.
13. McTernan PG, Fisher FM, Valsamakis G, Chetty R, Harte A, McTernan CL, Clark PM, Smith SA, Barnett AH, Kumar S. Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. J Clin Endocrinol Metab 2003, 88:6098-6106. 10.1210/jc.2003-030898, 14671216.
14. Silha JV, Krsek M, Skrha JV, Sucharda P, Nyomba BL, Murphy LJ. Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance. Eur J Endocrinol 2003, 149:331-335. 10.1530/eje.0.1490331, 14514348.
15. Szapary PO, Bloedon LT, Samaha FF, Duffy D, Wolfe ML, Soffer D, Reilly MP, Chittams J, Rader DJ. Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome. Arterioscler Thromb Vasc Biol 2006, 26:182-188. 10.1161/01.ATV.0000195790.24531.4f, 16284192.
16. Lehrke M, Reilly MP, Millington SC, Iqbal N, Rader DJ, Lazar MA. An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med 2004, 2(1):161-168.
17. Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. J Immunol 2005, 174:5789-5795.
18. Verma S, Li SH, Wang CH, Fedak PW, Li RK, Weisel RD, Mickle DA. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation 2003, 108:736-740. 10.1161/01.CIR.0000084503.91330.49, 12874180.
19. Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005, 111:932-939. 10.1161/01.CIR.0000155620.10387.43, 15710760.
20. Blaak EE. Fatty acid metabolism in obesity and type 2 diabetes mellitus. Proc Nutr Soc 2003, 62:753-760. 10.1079/PNS2003290, 14692611.
21. Sarafidis PA, Bakris GL. Non-esterified fatty acids and blood pressure elevation: a mechanism for hypertension in subjects with obesity/ insulin resistance?. J Hum Hypertens 2007, 21:12-19. 10.1038/sj.jhh.1002103, 17051236.
22. Nourooz-Zadeh J. Key issues in F2-isoprostane analysis. Biochem Soc Trans 2008, 36:1060-1065. 10.1042/BST0361060, 18793189.
23. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ. A{cyrillic} series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA 1990, 87:9383-9387. 10.1073/pnas.87.23.9383, 55169, 2123555.
24. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and_ -cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419. 10.1007/BF00280883, 3899825.
25. Committee E. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997, 20:1183-1189.
26. Phillips LK, Prins JB. The link between abdominal obesity and the metabolic syndrome. Curr Hypertens Rep 2008, 2008(10):156-164.
27. Pittas AG, Joseph NA, Greenberg AS. Adipocytokines and insulin resistance. J Clin Endocrinol Metab 2004, 89:447-452. 10.1210/jc.2003-031005, 14764746.
28. Beltowski J. Adiponectin and resistin-new hormones of white adipose tissue. Med Sci Monit. 2003, 9(2):55-61.
29. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA. The hormone resistin links obesity to diabetes. Nature 2001, 409:307-312. 10.1038/35053000, 11201732.
30. Banerjee RR, Rangwala SM, Shapiro JS, Rich AS, Rhoades B, Qi Y, Wang J, Rajala MW, Pocai A, Scherer PE, Steppan CM, Ahima RS, Obici S, Rossetti L, Lazar MA. Regulation of fasted blood glucose by resistin. Science 2004, 303:1195-1198. 10.1126/science.1092341, 14976316.
31. Rajala MW, Obici S, Scherer PE, Rossetti L. Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production. J Clin Invest 2003, 111:225-230. 151868, 12531878.
32. Rangwala SM, Rich AS, Rhoades B, Shapiro JS, Obici S, Rossetti L, Lazar MA. Abnormal Glucose Homeostasis due to Chronic Hyperresistinemia. Diabetes 2004, 53:1937-1941. 10.2337/diabetes.53.8.1937, 15189975.
33. Heilbronn LK, Rood J, Janderova L, Albu JB, Kelley DE, Ravussin E, Smith SR. Relationship between serum resistin concentrations and insulin resistance in nonobese, obese, and obese diabetic subjects. J Clin Endocrinol Metab 2004, 89:1844-1848. 10.1210/jc.2003-031410, 15070954.
34. Lee JH, Chan JL, Yiannakouris N, Kontogianni M, Estrada E, Seip R, Orlova C, Mantzoros CS. Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab 2003, 88:4848-4856. 10.1210/jc.2003-030519, 14557464.
35. Vozarova de Courten B, Degawa-Yamauchi M, Considine RV, Tataranni PA. High serum resistin is associated with an increase in adiposity but not a worsening of insulin resistance in Pima Indians. Diabetes 2004, 2004(53):1279-1284.
36. Hivert MF, Sullivan LM, Fox CS, Nathan DM, D'Agostino RB, Wilson PW, Meigs JB. Associations of adiponectin, resistin, and tumor necrosis factor-_ with insulin resistance. J Clin Endocrinol Metab 2008, 93:3165-3172. 10.1210/jc.2008-0425, 2515087, 18492747.
37. Yamamoto Y, Fujiuchi S, Hiramatsu M, Nishigaki Y, Takeda A, Fujita Y, Yamazaki Y. Resistin Is Closely Related to Systemic Inflammation in Obstructive Sleep Apnea. Respiration 2008, 76:377-385. 10.1159/000141866, 18577878.
38. Wysocka E, Cofta S, Dziegielewska S, Gozdzik J, Torlinski L, Batura-Gabryel H. Adipocytokines in sleep apnea syndrome. Eur J Med Res. 2009, 14(4):255-258. 10.1186/2047-783X-14-S4-255, 3521364, 20156767.
39. Curat CA, Wegner V, Sengenes C, Miranville A, Tonus C, Busse R, Bouloumie A. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 2006, 49:744-747. 10.1007/s00125-006-0173-z, 16496121.
40. Patel C, Macphee CH, Smith SA. Resistin is expressed in human macrophages and directly regulated by PPAR_ activators. Biochem Biophys Res Commun 2003, 300:427-476.
41. Li M, He XG, Qu SH, Zhan HM, Yang YB, Xu X, Si YF. Plasma resistin level in obstructive sleep apnea hypopnea syndrome. Zhonghua Yi Xue Za Zhi. 2008, 88(34):2399-2402.
42. Wasilewska J, Kaczmarski M, Sawicka-Zukowska M, Serum resistin level in pediatric obstructive sleep apnea. Thematic Poster Session Paediatric respiratory epidemiology I: primary ciliary dyskinesia, sleep-disordered breathing, exercise-induced symptoms and rare diseases 2008, Tuesday, 07 October 2008, Serum resistin level in pediatric obstructive sleep apnea. Thematic Poster Session.
43. Kunnari A, Ukkola O, Paivansalo M, Kesaniemi YA. High plasma resistin level is associated with enhanced highly sensitive C reactive protein and leukocytes. J Clin Endocrinol Metab 2006, 91:2755-2760. 10.1210/jc.2005-2115, 16608899.